Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center provide fresh insights about how cancers evolve when they metastasize – insights that could aid in developing strategies to improve the effectiveness of treatment.
A clinical trial in patients with advanced breast cancer has found the use of liquid biopsy blood tests for early detection of a treatment-resistant mutation, followed by a new type of treatment, substantially extends the period of tumor control.
A team of Cornell researchers is exploring how workplace tracking apps can be used not to surveil workers, but to help them build solidarity and improve their working conditions.
Smolka, a biochemist and former interim director of the Weill Institute for Cell and Molecular Biology, will support life sciences across the university.
Imprint, an organization founded at Cornell Tech that is dedicated to decoding the body’s immune memory and uncovering the causes of chronic diseases, announced that it has raised over $15 million in funding.
A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment, according to a study led by investigators at Weill Cornell Medicine.
Researchers at Weill Cornell Medicine have discovered that a parasite that causes malaria when transmitted through a mosquito bite can shut down a key set of genes, rendering itself “immunologically invisible” — sometimes for years.
